More than 25 years ago, Hartwell and Friend proposed the concept of harnessing synthetic lethality to treat cancers harbouring conventionally undruggable proteins with a role in oncogenesis arising from LOF mutations1,2. The excitement of using genetic principles as tools for cancer drug discovery was...
Synthetic lethality happens between two genes that the mutation of either gene is feasible but the mutation of both concurrently leads to viability loss. The key to the use of synthetic lethality during cancer therapy is the identification of stable synthetic lethal genetic interactions. The ...
Although synthetic lethality is not a new idea, recent advances, including CRISPR-based gene editing, have made possible systematic screens for synthetic lethal drug targets in human cancers. Such approaches have broad potential to drive the discovery of the next wave of genetic cancer targets and ...
The genetic concept of synthetic lethality has now been validated clinically through the demonstrated efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of cancers in individuals with germline loss-of-function mutations in either BRCA1 or BRCA2. Three different PARP inhibitors...
摘要 Synthetic lethality happens between two genes that the mutation of either gene is feasible but the mutation of both c... 收藏 全部来源 求助全文 Springer 相似文献 The concept of synthetic lethality in the context of anticancer thera...
Three dimensional culture of human breast cancer cells. Credit: NCI Center for Cancer Research Approach exploits tumor weaknesses when 2 genetic defects are combined. With advances in genome sequencing, cancer treatments have increasingly sought to leverage the idea of “synthetic lethality,” exploit...
参考: Lethal clues to cancer-cell vulnerability Synthetic lethality | Synthetic Lethal Interactions | BRCA Mutation & PARP Inhibition Cancer Vulnerabilities Unveiled by Genomic Loss- CELL 探针资本_行业研究:合成致死疗法
Therefore, it is possible that p300 inhibitors exhibit a synthetic lethal anticancer effect in CREBBP-deficient cancer cells by inhibiting the expression of MYC. This phenomenon provides a potential treatment for CREBBP-deficient cancers. Synthetic lethality induced by MLL gene fusion and DOT1L ...
different but complementary functions in the cell. Loss of the BRCA protein still allows the cell to survive but greatly increases its chances of becoming cancerous through the accumulation of mutations. The loss of both proteins, however, kills the cell in a process called synthetic lethality. ...
The development of cancer therapies is limited by the availability of suitable drug targets. Potential candidate drug targets can be identified based on the concept of synthetic lethality (SL), which refers to pairs of genes for which an aberration in either gene alone is non-lethal, but co-oc...